Huntington's disease (HD) is a genetic neurodegenerative disorder characterized by motor abnormalities and cognitive impairment. The irreversible succinate dehydrogenase (SD) inhibitor 3-nitropropionic acid (3NP) causes neurodegeration in the striatum resembling HD when administered to rodents or primates. Using corticostriatal brain slice preparations, we analyzed the pattern of gene expression following 3NP application utilizing cDNA microarrays. Acute 3NP treatment modulates the expression of several genes involved in dopaminergic and glutamatergic signaling in corticostriatal brain slices, and unbalances the downstream serine/threonine protein kinase and phosphatase network affecting the dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32). Our data provide new information about the molecular events possibly underlying neurodegeneration induced by this mitochondrial toxin.

Napolitano, M., Centonze, D., Gubellini, P., Rossi, S., Spiezia, S., Bernardi, G., et al. (2004). Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease. NEUROBIOLOGY OF DISEASE, 15(2), 407-414 [10.1016/j.nbd.2003.11.021].

Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease

CENTONZE, DIEGO;BERNARDI, GIORGIO;CALABRESI, PAOLO
2004-03-01

Abstract

Huntington's disease (HD) is a genetic neurodegenerative disorder characterized by motor abnormalities and cognitive impairment. The irreversible succinate dehydrogenase (SD) inhibitor 3-nitropropionic acid (3NP) causes neurodegeration in the striatum resembling HD when administered to rodents or primates. Using corticostriatal brain slice preparations, we analyzed the pattern of gene expression following 3NP application utilizing cDNA microarrays. Acute 3NP treatment modulates the expression of several genes involved in dopaminergic and glutamatergic signaling in corticostriatal brain slices, and unbalances the downstream serine/threonine protein kinase and phosphatase network affecting the dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32). Our data provide new information about the molecular events possibly underlying neurodegeneration induced by this mitochondrial toxin.
mar-2004
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/26 - NEUROLOGIA
English
Con Impact Factor ISI
Protein-Serine-Threonine Kinases; Propionic Acids; Oligonucleotide Array Sequence Analysis; Phosphoric Monoester Hydrolases; Phosphoproteins; Rats, Wistar; Succinate Dehydrogenase; Rats; Electron Transport Complex II; Neostriatum; Animals; Nitro Compounds; Huntington Disease; Glutamic Acid; Enzyme Inhibitors; Signal Transduction; Nerve Tissue Proteins; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Gene Expression Regulation, Enzymologic
Napolitano, M., Centonze, D., Gubellini, P., Rossi, S., Spiezia, S., Bernardi, G., et al. (2004). Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease. NEUROBIOLOGY OF DISEASE, 15(2), 407-414 [10.1016/j.nbd.2003.11.021].
Napolitano, M; Centonze, D; Gubellini, P; Rossi, S; Spiezia, S; Bernardi, G; Gulino, A; Calabresi, P
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/27088
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 21
social impact